Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE